A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic™M) in the treatment of migraine

Headache

Volumn 51, Issue 7, 2011, Pages 1078-1086

  Cady, Roger K ^a   Goldstein, Jerome ^b   Nett, Robert ^c   Mitchell, Russell ^d   Beach, M E ^e   Browning, Rebecca ^e  

^a HEADACHE CARE CENTER   (United States)

^b San Francisco Headache Clinic   (United States)

^c Texas Headache Associates   (United States)

^d PuraMed BioScience Inc   (United States)

^e Clinvest/A Division of Banyan Group Inc   (United States)

Author keywords

acute migraine; feverfew; ginger; herbal migraine treatment; over the counter

Indexed keywords

GINGER EXTRACT; GINGER EXTRACT PLUS TANACETUM PARTHENIUM EXTRACT; LIPIGESIC; PLACEBO; TANACETUM PARTHENIUM EXTRACT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANALGESIA; ARTICLE; ASTHMA; BACKACHE; BODY PAIN; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INFECTION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; NAUSEA; ORAL PARESTHESIA; PAIN; PAIN ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUS INFECTION; STOMACH CRAMP; STOMACH DISEASE; STOMACH FLU; TASTE DISORDER; VOMITING;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHILD; DOUBLE-BLIND METHOD; FEMALE; GINGER; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PAIN PERCEPTION; PHYTOTHERAPY; PILOT PROJECTS; PLANT PREPARATIONS; QUESTIONNAIRES; TANACETUM PARTHENIUM; YOUNG ADULT;

EID: 79960588812     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01910.x     Document Type: Article

References (18)

1. Monteith TS, Goadsby PJ,. Acute migraine therapy: New drugs and new approaches. Curr Treat Options Neurol. 2011; 13: 1-14. doi: 10.1007/s11940-010- 0105-6
2. Wenzel RG, Sarvis CA, Krause ML,. Over-the-counter drugs for acute migraine attacks: Literature review and recommendations. Pharmacotherapy. 2003; 23: 494-505. (Pubitemid 36384328)
3. Ng-Mak DS, Hu XH, Chen YT, Ma L,. Acute migraine treatment with oral triptans and NSAIDs in a managed care population. Headache. 2008; 48: 1176-1185.
4. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB,. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24: 483-490. (Pubitemid 38748030)
5. Snow V, Weiss K, Wall EM, Mottur-Pilson C, American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002; 137: 840-849. (Pubitemid 35334454)
6. Ferrari MD, Roon KI, Lipton RB, et al,. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675. (Pubitemid 33124324)
7. Cady RK, Schreiber CP, Beach ME, Hart CC,. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Med Sci Monit. 2005; 11: PI65-PI69. (Pubitemid 41330139)
8. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF,. Migraine in the United States: Epidemiology and patterns of health care use. Neurology. 2002; 58: 885-894. (Pubitemid 34242063)
9. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754-762.
10. Lipton RB, Stewart WF, Stone AM, Láinez MJ, Sawyer JP,. Disability in strategies of care study group. Stratified care vs. step care strategies for migraine: The Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000; 284: 2599-2605.
11. Goadsby PJ,. The "Act when Mild" (AwM) study: A step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008; 28 (Suppl. 2): 36-41.
12. Winner P, Landy S, Richardson M, Ames M,. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther. 2005; 27: 1785-1794. (Pubitemid 41815229)
13. Gallagher RM, Kunkel R,. Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache. 2003; 43: 36-43. (Pubitemid 36150988)
14. Ng-Mak DS, Cady R, Chen YT, Ma L, Bell CF, Hu XH,. Can migraineurs accurately identify their headaches as migraine at attack onset? Headache. 2007; 47: 645-653. (Pubitemid 46733714)
15. Cady RK, Sheftell F, Lipton RB, et al,. Early treatment with sumatriptan enhances pain-free responses: Retrospective analysis from three clinical trials. Clin Ther. 2000; 22: 1035-1048.
16. Loder EW, Sheftell F,. The quality of headache treatment in the United States: Review and analysis of recent data. Headache. 2005; 45: 939-946. (Pubitemid 41045374)
17. MacGregor EA, Brandes J, Eikermann A,. Migraine prevalence and treatment patterns: The global Migraine and Zolmitriptan Evaluation survey. Headache. 2003; 43: 19-26. (Pubitemid 36150986)
18. Aviram A, Tsoukias NM, Melnick S, Ramachandran C,. Inhibition of nitric oxide production by feverfew supercritical extract as part of a migraine model in vitro. FASEB Experimental Biology 2009 Annual Meeting in New Orleans, LA, April 18-22, 2009. FASEB J. 2009; 23: 902.3.